# OnCo record tafasitamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tafasitamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tafasitamab" ;
  schema:name "Tafasitamab"@en ;
  schema:description "A CD19 antibody given with lenalidomide for lymphoma patients who cannot have a transplant; in 2026 it showed the first frontline gain over R-CHOP in high-risk disease."@en ;
  schema:url <https://onco.cc/drugs/tafasitamab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tafasitamab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q98078915> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tafasitamab> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-CD19, Fc-enhanced)" ;
  schema:alternateName "Monjuvi" ;
  onco:approval "US 2020: R/R DLBCL with lenalidomide, transplant-ineligible (accelerated)", "US 2025: R/R follicular lymphoma with lenalidomide and rituximab", "EU 2021: EU brand Minjuvi" ;
  onco:acceleratedApproval "US 2020-07-31: In combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)." ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/lenalidomide/> ;
  onco:companies <https://onco.cc/companies/incyte/>, <https://onco.cc/companies/morphosys/> ;
  onco:terms <https://onco.cc/terms/adcc/> ;
  onco:trials <https://onco.cc/trials/l-mind/>, <https://onco.cc/trials/frontmind/>, <https://onco.cc/trials/nct05429268/>, <https://onco.cc/trials/nct04680052/>, <https://onco.cc/trials/nct05222555/>, <https://onco.cc/trials/nct03930953/>, <https://onco.cc/trials/nct06465433/> .